AI
PTGX icon

Axiom Investors’s Protagonist Therapeutics PTGX Stock Holding History

Axiom Investors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10M Sell
81,683
-3,792
-4% -$396K 0.09% 86
2026
Q1 		$9.01M Sell
85,475
-3,993
-4% -$354K 0.1% 81
2025
Q4 		$7.81M Buy
89,468
+9,355
+12% +$766K 0.07% 95
2025
Q3 		$5.32M Buy
80,113
+28,880
+56% +$1.64M 0.04% 98
2025
Q2 		$2.83M Buy
51,233
+11,264
+28% +$541K 0.02% 116
2025
Q1 		$1.93M Buy
+39,969
New +$1.67M 0.02% 122

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Axiom Investors's PTGX Position: Q2 2026 in Review

Axiom Investors reduced its Protagonist Therapeutics (PTGX) stake by 4.4% in Q2 2026, selling an estimated $396K and leaving 81,683 shares worth $10M. The position accounts for 0.09% of the portfolio, ranked #86.

Axiom Investors first reported a position in PTGX in Q1 2025 and has held it in 6 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Axiom Investors held 81,683 shares of Protagonist Therapeutics worth $10M as of Q2 2026.
  • Axiom Investors sold 3,792 Protagonist Therapeutics shares in Q2 2026, an estimated $396K.
  • Protagonist Therapeutics made up 0.09% of Axiom Investors's portfolio in Q2 2026, its #86 holding.
  • Axiom Investors first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Axiom Investors's 13F filing for Q2 2026, filed 12 Aug 2026.